Role of cytokines in development of endometriosis

我们检测了子宫内膜异位症患者腹腔液（PF）中基质金属蛋白酶-9（MMP-9）及其抑制剂、金属蛋白酶组织抑制剂-1（TIMP-1）和白细胞介素-10（IL-10）的水平。虽然MMP-9的浓度低于检测水平，但PF中存在高浓度的TIMP-1和IL-10。子宫内膜异位症患者PF中IL-10的水平显著高于非子宫内膜异位症患者。为了检查IL-6或IL-10对TIMP-1基因表达的影响，从子宫或卵巢巧克力囊肿收集子宫内膜和子宫内膜异位基质细胞。本研究旨在探讨IL-6、可溶性IL-6受体在子宫内膜和子宫内膜异位症细胞生长中的可能作用。本研究检测了IL-6、可溶性IL-6受体或两者联合对子宫内膜和子宫颈癌细胞增殖的影响。 ...更多信息 间质细胞IL-6受体对增殖期组织中基质细胞的生长没有影响。相反，加入200或400 pg/ml的IL-6诱导细胞增殖显著抑制。同样地，可溶性IL-6受体的加入导致分泌期组织中子宫内膜间质细胞的生长受到显著抑制，但不抑制增殖期。另一方面，增生组织的基质细胞对IL-6具有抗性，没有显示出抑制反应。虽然联合处理不影响增殖期基质细胞和增生组织的增殖，但在存在1 ng/ml可溶性IL-6受体的情况下，10 gn/ml可溶性IL-6抑制分泌期基质细胞的增殖。IL-6受体和gp 130的转录本在增殖期、分泌期子宫内膜细胞和增生期子宫内膜细胞中均有表达。IL-6可能作为内分泌作用的介质在调节子宫内膜细胞的生长中发挥中心作用。子宫内膜异位症细胞的行为可能与正常对应物在IL-6的抑制性调节方面不同。少

We have measured peritoneal fluid (PF) levels of matrix metalloproteinase-9 (MMP-9), its inhibitor, tissue inhibitor of metalloproteinase-1 (TIMP-1) and interleukin-10 (IL-10) in patients with endometriosis. Although the concentrations of MMP-9 was below the detectable level, high concentrations of TIMP-1 and IL-10 were present in the PF. The levels of IL-10 in PF was significantly higher in patients with endometriosis than in patients without endometriosis. In order to examine the effects of IL-6 or IL-10 on the gene expression of TIMP-1, endometrial and endometriotic stromal cells were collected from the uterus or from ovarian chocolate cysts. The stimulatory effects of these cytokines have been elucidated.We have conducted the study to investigate the possible role of IL-6, soluble IL-6 receptor in the growth of endometrial and endometriotic cells. We examined the effect of IL-6, soluble IL-6 receptor or combination of both factors on the proliferation of endometrial and endometriot … More ic stromal cells. IL-6 receptor had no effect on the growth of stromal cells in tissue from the proliferative phase. In contrast, the addition of 200 or 400pg/ml of IL-6 induced significant inhibition of cell proliferation. Similarly, the addition of soluble IL-6 receptor caused significant suppression in the growth of endometrial stromal cells in tissue from the secretory phase, but not the proliferative phase. On the other hand, stromal cells of endometriotic tissues were resistant to IL-6, showing no inhibitory response. Although the combination treatment did not affect the proliferation of stromal cells of proliferative phase and of endometriotic tissues, 10gn/ml of soluble IL-6 inhibited proliferation of stromal cells of the secretory phase in the presence of 1ng/ml of soluble IL-6 receptor. The expression of transcripts of IL-6 receptor and gp130 was observed in the endometrial cells from the proliferative and secretory phases and in endometriotic cells. IL-6 may play a central role in regulation of the growth of endometrial cells as a mediator of endocrine action. Endometriotic cells may behave differently from the normal counterpart in terms of the inhibitory regulation exerted by IL-6. Less